Real-life use of elbasvir/grazoprevir in adults and elderly patients: a prospective evaluation of comedications used in the PITER cohort
| Autor: | Quaranta M. G., Rosato S., Ferrigno L., Amoruso D. C., Monti M., Di Stefano P., Filomia R., Biliotti E., Migliorino G., Russo F. P., Degasperi E., Chemello L., Brancaccio G., Blanc P., Cannizzaro M., Barbaro F., Morsica G., Licata A., Kondili L. A., on behalf of PITER Collaborating group, Federico A., Dallio M., Loguercio C. |
|---|---|
| Přispěvatelé: | Quaranta, M. G., Rosato, S., Ferrigno, L., Amoruso, D. C., Monti, M., Di Stefano, P., Filomia, R., Biliotti, E., Migliorino, G., Russo, F. P., Degasperi, E., Chemello, L., Brancaccio, G., Blanc, P., Cannizzaro, M., Barbaro, F., Morsica, G., Licata, A., Kondili, L. A., on behalf of PITER Collaborating, Group, Federico, A., Dallio, M., Loguercio, C., Quaranta M.G., Rosato S., Ferrigno L., Amoruso D.C., Monti M., Di Stefano P., Filomia R., Biliotti E., Migliorino G., Russo F.P., Degasperi E., Chemello L., Brancaccio G., Blanc P., Cannizzaro M., Barbaro F., Morsica G., Licata A., Kondili L.A. |
| Rok vydání: | 2020 |
| Předmět: |
Male
030312 virology combination therapy treatment experienced patients Drug Combination chronic hepatitis C drug drug interactions virus genotype 1 treatment experienced patients pump inhibitor use combination therapy treatment naive liver fibrosis grazoprevir elbasvir 80 and over Age Factor Pharmacology (medical) Drug Interactions Prospective Studies Chronic Prospective cohort study liver fibrosis Aged 80 and over 0303 health sciences Age Factors Imidazoles Middle Aged Hepatitis C Drug Combinations Infectious Diseases Treatment Outcome Drug Interaction Grazoprevir Cohort drug drug interactions Female pump inhibitor use Human medicine.drug medicine.medical_specialty Elbasvir Quinoxaline treatment naive elbasvir Antiviral Agents NO 03 medical and health sciences Internal medicine Quinoxalines medicine chronic hepatitis C Elbasvir Grazoprevir Humans Imidazole Aged Benzofurans Antiviral Agent Pharmacology business.industry grazoprevir Carbamazepine Hepatitis C Chronic medicine.disease Comorbidity Discontinuation Benzofuran business virus genotype 1 |
| Zdroj: | Antiviral therapy. 25(2) |
| ISSN: | 2040-2058 |
| Popis: | Background In patients treated for HCV infection, potential drug–drug interactions (DDIs) can occur among direct-acting antiviral drugs (DAAs) and comedications used. The real-life effectiveness and safety of elbasvir/grazoprevir (ELB/GZR) among co-medicated HCV patients was evaluated. Methods We prospectively evaluated consecutive patients from 15 clinical centres participating in PITER who were treated with ELB/GZR and had been followed for at least 12 weeks after treatment. Data were prospectively collected on the use of comedications (including discontinuation, dose modification and addition of drugs) and potential DDIs with DAAs. Results Of the 356 patients with at least 12-week post-treatment follow-up (median age 67, range 50–88 years), 338 (95%) achieved sustained virological response. Of these, 219 (60%) had at least one comorbidity (median 2, range 1–6); information on comedication was available for 212 of them. Of 190 comedications used, 15 (8%) drugs were modified during ELB/GZR therapy, specifically in 9 (4%) patients they were interrupted, in 2 (1%) of whom, the comedication was interrupted before the DAA therapy because of potential DDI (that is, patients treated with carbamazepine); in 12 (6%) patients the comedications were modified in terms of dosage. In 29 (14%) patients, the comedications required monitoring when used with ELB/GZR, as well as with all available DAAs. Of the 190 drugs, 27 (14%) used in 67% of patients were free of DDIs when used with ELB/GZR, whereas they required monitoring if used with other DAA regimens. Conclusions The results of this prospective study support findings that ELB/GZR is effective and safe in most treated patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|